Prosecution Insights
Last updated: November 04, 2026

Imunexus Therapeutics Limited

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Imunexus Therapeutics Limited currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This active case is being processed by 1 distinct examiner, showing a singular focus for the portfolio's current prosecution. The data also shows that 1 distinct art unit is involved, which points to a specific regulatory focus within the pharmaceutical sector. Such concentration allows for a targeted legal approach but centralizes risk on a single examiner's decision regarding the 1 pending action.

The busiest examiner assigned to this portfolio is BRISTOL, LYNN ANNE, who is managing 1 pending office action. As the only examiner with an active case, BRISTOL, LYNN ANNE is responsible for the full scope of the portfolio's current pending workload. This arrangement requires the applicant to focus their immediate legal strategy on the requirements and precedents of the 1 art unit involved. The prosecution path is currently defined by this single examiner's review of the company's biotechnology filings, providing a clear but narrow route to potential patent issuance.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
0
Medium (0%)
1
Easy (100%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§112 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BRISTOL, LYNN ANNE 1 63.4% +39.7%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18239052 Multi-Specific Molecules BRISTOL, LYNN ANNE 28d

Top Art Units

Art UnitApps
1643 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18239052 Multi-Specific Molecules BRISTOL, LYNN ANNE 1643 §112 Final Rejection 28d Pending Aug 28, 2023

Managing Imunexus Therapeutics Limited's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Imunexus Therapeutics Limited have?

Imunexus Therapeutics Limited has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Imunexus Therapeutics Limited applications?

Lynn Anne Bristol has the most, with 1 of Imunexus Therapeutics Limited's pending office actions.

What technology area are Imunexus Therapeutics Limited's patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month